bioAffinity Technologies, Inc. 8-K

What Happened

• On May 27, 2026, bioAffinity Technologies, Inc. (a Delaware corporation) filed an 8-K (Item 8.01) reporting that it received notification of allowance from the Mexican Institute of Industrial Property for a patent application. The patent application covers methods of predicting the likelihood of lung cancer using flow cytometry. The company attached a press release (Exhibit 99.1) to the filing.

Key Details

• Filing date: May 27, 2026 (Form 8-K, Item 8.01).
• Office granting allowance: Mexican Institute of Industrial Property.
• Subject: methods for predicting likelihood of lung cancer using flow cytometry.
• Press release announcing the allowance is included as Exhibit 99.1 to the 8-K.

Why It Matters

• This allowance expands bioAffinity’s intellectual property protection in Mexico for a diagnostic method tied to lung cancer detection, which can help support commercialization, licensing, or partnership efforts in that market.
• The filing does not disclose financial impacts, timelines to patent issuance, or projected revenue; investors should view this as an IP development (not a revenue announcement) until the company provides further commercial or financial guidance.